ALTANA Has Withdrawn the EU Marketing Authorisation Application for Daxas

ALTANA Pharma has taken this decision after consulting with theEMEA today. The submission of a new MAA will be pursued, after furtherclinical data are available.

ALTANA Pharma is committed to continue the development of Daxas(R)and will pursue further clinical studies to strengthen theanti-inflammatory product profile and possible market potential ofDaxas(R).

The phosphodiesterase4 (PDE4)-inhibitor Daxas(R) (roflumilast) isan oral investigational, steroid free anti-inflammatory agent beingstudied for the treatment of chronic obstructive pulmonary disease(COPD) and asthma.

This press release contains forward-looking statements, i.e.,current estimates or expectations of future events or future resultssuch as the expected submission of a new MAA for Daxas and expectedfurther clinical data. These statements are based on beliefs ofALTANA's management as well as assumptions made by and informationcurrently available to ALTANA. Many factors that ALTANA is unable topredict with accuracy could cause ALTANA's actual results to bematerially different from those that may be expressed or implied bysuch forward-looking statements.

Forward-looking statements speak only as of the date they aremade. ALTANA does not intend, and does not assume any obligation, toupdate forward-looking statements to reflect facts, circumstances orevents that have occurred or changed after such statements have beenmade.

www.altana.com